CSafe joins BioLife’s global partner network of cold chain solution providers serving the CGT market. BioLife expects to support 10,000-12,000 evo shipments of CGT starting materials and manufactured doses over the next 12 months. The new partnership will provide expanded supply chain options for any CGT product, at any stage of development, from early clinical-phase trials to global commercial scale.
Leveraging CSafe’s global reach to the CGT sector, this new alliance will operate from 50+ service centers worldwide, for biopharmaceutical manufacturers looking to navigate supply chain complexity.
“CSafe is honored to partner with the team at BioLife Solutions, whose range of CGT bioproduction tools and services is peerless in the market. We are excited to merge these exceptional tools and services with our expertise in global, reliable scaled delivery,” said CSafe CEO Patrick Schafer. “CGT is hitting its stride and needs global support. We know how important these therapies are to patients everywhere, and it’s our mission at CSafe to protect every shipment.”
“We’re excited to work with a global partner with a strong history of reliability and performance and a deep dedication to innovative therapies,” said BioLife Solutions CEO Mike Rice. “We have the best LN2 technology and cGMP storage facilities in the market, in addition to our other world-class CGT solutions, and we are confident our collaboration with CSafe will extend our reach and result in even more reliability and real-time service for CGT partners.”
